Clinical study on the effect of Shengxueling on idiopathic thrombocytopenic purpura.
OBJECTIVE
To observe the clinical effect of Shengxueling (SXL) on idiopathic thrombocytopenic purpura (ITP), and study the possible mechanism.


METHODS
Eighty-six cases of ITP were randomly divided into two groups. The SXL group, 56 patients treated with SXL, a traditinal Chinese medicine and 30 patients administered with prednisone were taken as control. Each group took drugs for 3 months and was under follow-up observation.


RESULTS
In the SXL group, the total effective rate was 85.71%, similar to prednisone 83.33% (P > 0.05) for 3 months, but the total effective rate of SXL (91.07%) were obviously better than that of the control group (53.33%) (P < 0.01) for 6 months and had no obvious adverse reaction. The patients bleeding was alleviated or stopped, the general condition was improved. At the same time, blood platelet count (PLT) was increased, platelet associated immunoglobulin (PAIg) and interleukin-4 (IL-4) were markedly dropped, the level of natural killers cells activity (NKa) increased, the rate of T lymphocyte subsets gradually returned to normal level. Megakaryocyte tended to maturation on bone marrow smear after treatment. All differences above were statistically significant.


CONCLUSIONS
SXL is an effective and safe medicine for ITP. Its mechanism could regulate cytoimmune, inhibit platelet antibody to reduce the destruction of platelet, increase the number of platelet, promote the division and maturation of megakaryocyte, facilitate the production and release of platelet, lower the fragility of capillary, prevent and cure hemorrhagic tendency.
Zhou
Yong-ming
YM
Yueyang Hospital of Integrated Traditional and Western Medicine, Shanghai University of TCM, China. yongmingz@sohu.com
Huang
Zhen-qiao
ZQ
Hu
Ming-hui
MH
Zhou
Shao-hong
SH
Huang
Tao
T
Xu
Yi
Y
Lu
Jia-Hui
JH
Gan
Xiao-fang
XF
Zhu
Wen-wei
WW
D000293:Adolescent; D000328:Adult; D001792:Blood Platelets / Q000378:metabolism; D001853:Bone Marrow / Q000473:pathology; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006470:Hemorrhage / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D007136:Immunoglobulins / Q000097:blood; D015847:Interleukin-4 / Q000097:blood; D007694:Killer Cells, Natural / Q000473:pathology; D018655:Lymphocyte Count; D008297:Male; D008516:Medicine, Chinese Traditional; D008875:Middle Aged; D008517:Phytotherapy / Q000009:adverse effects; D028321:Plant Preparations / Q000009:adverse effects / Q000627:therapeutic use*; D010976:Platelet Count; D011241:Prednisone / Q000627:therapeutic use; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000097:blood / Q000150:complications / Q000473:pathology / Q000628:therapy*; D016176:T-Lymphocyte Subsets / Q000473:pathology; D016896:Treatment Outcome
D005938:Glucocorticoids; D007136:Immunoglobulins; D028321:Plant Preparations; D015847:Interleukin-4; D011241:Prednisone